Decoy Therapeutics, Inc. (DCOY) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4

Key dataNov 4, 2026

Open$1.15

From 52W high−97.03%

Volume16601.00

Market cap$2.72M

P/E (TTM)—

P/S (TTM)—

Div yield—

Key dataNov 4, 2026

Open

$1.15

From 52W high

−97.03%

Volume

16601.00

Market cap

$2.72M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

0.4x

P/E (TTM)

—

RSI (14)

37.8

MomentumView details →

1D Return

+2.70%

YTD Return

−85.43%

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

0.4x

EV/Sales

—

P/S (TTM)

—

P/B (TTM)

0.6x

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−334.41%

ROA (TTM)

−160.53%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

—

EPS YoY

+48.31%

FCF YoY

—

Revenue CAGR 3Y

—

EPS CAGR 3Y

+70.10%

EBITDA YoY

—

MomentumView details →

1D Return

+2.70%

YTD Return

−85.43%

1Y Return

−96.86%

RSI (14)

37.8

vs 50D SMA

−44.40%

vs 200D SMA

−78.86%

Capital & dividendView details →

Debt/Equity

0.00x

Current Ratio

1.83x

Quick Ratio

1.83x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$4.46

EPS Surprise

−54.86%

Beats (12Q)

7/12

Next Q EPS Est

−$1.11

Avg Surprise (4Q)

29.47%

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−14.45M

Op. CF (TTM)

−8.32M

Next earningsNov 13, 2026 →

Latest newsMore news →

Decoy Therapeutics Inc. reported $8.1 million in cash on its balance sheet as of September 30, 2026.1d ago

Decoy Therapeutics reported preclinical pharmacokinetic data showing that a single intranasal dose of its DCOY-CoV program candidate sustains drug levels above designed therapeutic concentrations for up to 7 days in nasal mucosal and lung tissue.36d ago

Similar companies

NeuroSense Therapeutics Ltd.NRSN Silo Pharma, Inc.SILO BioAtla, Inc.BCAB Affimed N.V.AFMD VivoSim Labs, Inc.VIVS Estrella Immunopharma, Inc.ESLAW Find similar companies →

Latest newsMore news →

Decoy Therapeutics Inc. reported $8.1 million in cash on its balance sheet as of September 30, 2026.1d ago Decoy Therapeutics reported preclinical pharmacokinetic data showing that a single intranasal dose of its DCOY-CoV program candidate sustains drug levels above designed therapeutic concentrations for up to 7 days in nasal mucosal and lung tissue.36d ago